Companies / PTX

PRESCIENT THERAPEUTICS LIMITED

ASX:PTXPharmaceuticals, Biotechnology & Life Sciences
1.05B shares on issueASX (delayed) · as of 28 July 2026$0.084price · delayed$96.7Mmarket cap · indicative
C
Dilution grade

Runway 2–4 quarters; 2 cash raises in 24 months; share count grew 8% in 24 months

Cash runway2.8 quarters of funding
Share-count growth (24m)7.6%
Raise cadence (24m)2 cash raises
Options & rights overhang2.6% of shares
In-the-money supply2.4% of shares
Pending proposed issuesnone

PRESCIENT THERAPEUTICS LIMITED's ordinary share count rose 7.6% between August 2025 and August 2025 to 1.05B shares. The company raised capital twice in the 24‑month window for total disclosed proceeds of A$16.8M, most recently A$9.8M in July 2025. Options and rights on issue could convert into 28M new shares, equal to 2.6% of the current share count, of which 2% are in the money at the current share price; the nearest expiry is November 2026. At the June 2026 quarter the company reported A$8.1M in available cash, covering about 2.8 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
2.6%
Max option dilution
2.4%
ITM option dilution
1
Raises · last 12 months
2.8 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.05B per ASX (delayed) (28 July 2026).
857.0M928.4M999.8MDec 24Sept 25July 26Cash raise · 28 July 2025Cash raise · 1 July 2025

Cash runway

2.8 qtrs
Two to four quarters of funding at the recent spend rate.
$8.1M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
10 July 20263H · cancellationPTX : ORDINARY FULLY PAID1.05BAppendix 3H
19 Dec 20253G · unquotedPTX : ORDINARY FULLY PAID1.05BAppendix 3G
17 Nov 20253G · unquotedPTX : ORDINARY FULLY PAID1.05BAppendix 3G
1 Sept 20253G · unquotedPTX : ORDINARY FULLY PAID1.05BAppendix 3G
29 Aug 20252A · quoted issuePTX : ORDINARY FULLY PAID1.05BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$9.8M
Capital raise
28 July 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

2.6%
Total overhang · of current shares
2.4%
In the money · at current price
27.8M
Potential new shares
Nov 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
18 Nov 2025Ellen Gwen FeigalOther—1.2M—3Y notice
18 Nov 2025Allen James Ebens Jr.Other—2.6M—3Y notice
18 Nov 2025James CampbellOther1.4M5.3M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PJune 2026 Quarterly Update and Appendix 4C
10 July 2026Notification of cessation of securities - PTX
11 June 2026PTX Dr Rosalind Wilson appointed as Chief Medical Officer
14 May 2026$PResponse to ASX Price Query
29 Apr 2026Investor Presentation
29 Apr 2026$PMarch 2026 Quarterly Update and Appendix 4C
24 Feb 2026Updated Securities Trading Policy
24 Feb 2026$PAppendix 4D and Half Year Financial Report
29 Jan 2026$PDecember 2025 Quarterly Update and Appendix 4C
19 Dec 2025Notification regarding unquoted securities - PTX
14 Dec 2025$PPTX secures EU Authorisation to commence PTX-100 Trial
20 Nov 2025Change of Director's Interest Notice
20 Nov 2025Change of Director's Interest Notice
20 Nov 2025Change of Director's Interest Notice
20 Nov 2025Change of Director's Interest Notice
20 Nov 2025Change of Director's Interest Notice
18 Nov 2025$PPTX secures EU Orphan Drug Designation for PTX-100 in CTCL
17 Nov 2025Notification regarding unquoted securities - PTX
28 Oct 2025Amended Constitution
14 Oct 2025Results of Annual General Meeting

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.